ArticleScientific reports2018
AEBP1 promotes epithelial-mesenchymal transition of gastric cancer cells by activating the NF-κB pathway and predicts poor outcome of the patients.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 55 citations in OpenAlex.
- TWIST1 drives endothelial-to-mesenchymal-transition to stabilize atherosclerotic plaques.Nature communications · 2026Article
- Elucidating the Predominant Role of AEBP1 in Different Types of Cancers with a Focus on Glioblastoma Progression - A Review.Current gene therapy · 2026Review
- Pan-Cancer Analysis Reveals AEBP1-Collagen Co-Expression and Its Potential Role in CAF-Mediated Tumor Stiffness.International journal of molecular sciences · 2025Article
- AEBP1-GLI1 pathway attenuates the FACT complex dependency of bladder cancer cell survival.Biochemistry and biophysics reports · 2025Article
- Silencing of AEBP1 inhibits proliferation and promotes apoptosis via the AKT signaling pathway in osteosarcoma.Biomedical reports · 2025Article
- Aggressive serous ovarian cancer subtype defined by high centrality lncRNA profiles and master transcription factors.Scientific reports · 2025Article
- AEBP1 inhibition reduces cell growth and PI3K/AKT pathway while less regulates cell mobility in hepatocellular carcinoma.World journal of surgical oncology · 2025Article
- To construct and validate a risk score model of angiogenesis-related genes to predict the prognosis of hepatocellular carcinoma.Scientific reports · 2025Article
- A novel Wnt/β-catenin signaling gene signature for progression and metastasis of gastric cancer.Oncology research · 2025Article
- Comprehensive evaluation of immunological attributes and immunotherapy responses of positive T cell function regulators in colorectal cancer.BMC gastroenterology · 2024Article
- Transcriptome sequencing reveals non-coding RNAs respond to porcine reproductive and respiratory syndrome virus andJournal of animal science and technology · 2024Article
- AEBP1 promotes papillary thyroid cancer progression by activating BMP4 signaling.Neoplasia (New York, N.Y.) · 2024Article
- ACLP Activates Cancer-Associated Fibroblasts and Inhibits CD8+ T-Cell Infiltration in Oral Squamous Cell Carcinoma.Cancers · 2023Article
- Inhibition of AEBP1 predisposes cisplatin-resistant oral cancer cells to ferroptosis.BMC oral health · 2022Article
- Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones.Nature communications · 2022Article
- Effects of alternative splicing events and transcriptome changes on kidney stone formation.Urolithiasis · 2022Article
- High expression of transmembrane P24 trafficking protein 9 predicts poor prognosis in breast carcinoma.Bioengineered · 2021Article
- AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses.Annals of translational medicine · 2021Article
- Carcinoembryonic antigen as a specific glycoprotein ligand of rBC2LCN lectin on pancreatic ductal adenocarcinoma cells.Cancer science · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Adipocyte enhancer binding protein 1 (AEBP1) is a transcriptional repressor that plays a critical role in regulating adipogenesis. Recent studies have indicated that AEBP1 might function as a candidate oncogene and is overexpressed in several human malignancies. However, the role of AEBP1 in gastric cancer (GC) remains largely unknown. This study aimed to investigate the expression pattern, prognostic significance and biological function of AEBP1 in human gastric cancer and to explore the underlying mechanism. We found that both the mRNA and protein levels of AEBP1 were significantly increased in human GC tissues. Elevated AEBP1 expression was significantly correlated with poor overall survival in patients with both early-stage (Tumor, Node, Metastases (TNM) TNM I and II) and late-stage (TNM III and IV) GC. Silencing AEBP1 markedly suppressed the proliferation, migration, invasion, metastasis and epithelial-mesenchymal transition of GC cells. Moreover, we demonstrated that knockdown of AEBP1 in GC cells led to inhibition of the NF-κB pathway by hampering the degradation of IκBα. Thus, AEBP1 might be served as a promising prognostic indicator and a potential therapeutic target in human GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.